Hormonal
Testosterone therapy in transgender men is effective for virilization, with higher doses achieving effects faster but not resulting in greater final outcomes compared to lower doses over the intermediate term.
For trans men, testosterone therapy effectively causes virilization. While higher doses might speed up early changes, they do not produce better results than lower doses after six months. It is safer to start with a lower dose and titrate up to a target range (300-1,000 ng/dL) to minimize risks while achieving the same physical changes.
Nakamura et al. (10) showed that early onset of treatment effects of testosterone therapy is dose-dependent, but within six months of initiating therapy, higher doses are no more effective than lower doses. Therefore, while higher doses may achieve desirable effects sooner, the risks associated with fast titration need to be assessed, and patients should be aware that testosterone effects eventually become the same over the intermediate-term.
Why this rating
Based on a specific study (Nakamura et al.) cited in the review; the review itself is a narrative review, not a primary trial.
Source
Hormone therapy for transgender patients
Cécile A. Unger · Translational Andrology and Urology · 2016
DOI 10.21037/tau.2016.09.04
More from this paper
- Ethinyl estradiol is strongly associated with an increased risk of cardiovascular events and should be avoided in transgender women; oral and transdermal estradiol are preferred.Good
- Cross-sex hormone therapy (testosterone for trans men, estrogen/anti-androgens for trans women) significantly improves quality of life, mood, and reduces perceived stress and cortisol levels.Moderate
- Long-term cross-sex hormone therapy does not increase the occurrence of cardiovascular events (myocardial infarction, DVT, cerebrovascular events) in transgender men, despite some negative changes in metabolic risk factors.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →